Fundraising Fox
/Companies
Sign in

Hyperion Therapeutics

Brisbane, US · 3 known investors

Find your way into Hyperion Therapeutics

Sign up to see every warm intro you have to Hyperion Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Hyperion Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Addressing unmet needs in gastroenterology and hepatology. (NASDAQ: HPTX) (Acquired Horizon Therapeutics)

Biotech

Founders & leadership

CN
Christine NashExecutive
NHNatalie Holles
Natalie HollesSVP, Corporate & Business Development2013–2015Director at Renasant Bio
AG
Ashley GouldExecutive
DJ
Donald J. SantelExecutive
KA
Klara A. DickinsonExecutive
BF
Bruce F. ScharschmidtExecutive
JS
Jeffrey S. FarrowExecutive

Board

JRJake R. Nunn
Jake R. NunnBoard Member2009–2015Partner at SR One Capital Management
BSBijan Salehizadeh
Bijan SalehizadehBoard Member2006–2015Managing Director at NaviMed Capital
BJ
Bo Jesper HansenBoard director
DG
Daniel G. WelchBoard director
LS
Lota S. ZothBoard director

Investors · 3

Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M

How we know: Sofinnova Ventures's portfolio page · Not right? Tell us

New Enterprise Associates (NEA)reportedMenlo Park · $200K – $40M

How we know: a partner's Signal profile · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$8M disclosed across 1 round · 2014

▶$8MraisedJun 2014 · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Bo Jesper HansenDirector
  • Christine NashExecutive Officer
  • Natalie HollesExecutive Officer
  • Jake R. NunnDirector
  • Bijan SalehizadehDirector
  • Daniel G. WelchDirector
  • Ashley GouldExecutive Officer
  • Lota S. ZothDirector
  • Donald J. SantelExecutive Officer
  • Klara A. DickinsonExecutive Officer
  • Bruce F. ScharschmidtExecutive Officer
  • Jeffrey S. FarrowExecutive Officer
  • James I. HealyDirector
Offering amount
$8M
Amount sold
$8M
First sale
Jun 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Hyperion Therapeutics do?
Addressing unmet needs in gastroenterology and hepatology. (NASDAQ: HPTX) (Acquired Horizon Therapeutics)
Who are Hyperion Therapeutics's investors?
Hyperion Therapeutics's investors include Bay City Capital, Sofinnova Ventures, New Enterprise Associates (NEA).
How much funding has Hyperion Therapeutics raised?
Hyperion Therapeutics has disclosed $8M raised across 1 round.
Where is Hyperion Therapeutics headquartered?
Hyperion Therapeutics is headquartered in Brisbane, US.